In the autumn of 2015, at the then 20-year-old Ania, routine research led to the diagnosis by doctors - a malignant ovarian tumor. Immediate tumor resection and complementary chemotherapy led to remission that lasted until summer 2017. The next treatment kept the disease in check until next autumn. This time the treating physician made a decision about more aggressive therapy, but it also did not bring the expected results. There are changes in the peritoneum and ... obstacles in the reimbursement of further treatment. Ania heard that he was a "non-deceitful patient." Despite the logs thrown under his feet, they managed to fight for the next infusions, but they did not prove effective.The latest tomography showed extensive dissemination of the cancer not only in the peritoneum, but also in the liver.
After such devastating results of research, Ania was consulted overnight to the Berlin team of doctors at the Charité Berlin oncology clinic. The success of consultations
in Berlin, it is possible to immediately implement experimental chemotherapy
as part of clinical trials. Support for this treatment will be
the so-called. organotherapy. It has the task of regenerating tissues, preventing the development of the disease, more comfortable with chemotherapy. This therapy is highly effective, patented and approved for treatment. Unfortunately - it is not used or refunded
Organotherapy is associated with costs that Anna and her relatives will not be able to bear. The possibility of implementing this therapy restored everyone's hope. In the end - it comes
for the life of an extremely talented and sensitive young woman.